What's Happening?
Rep. Andy Barr (R-KY) has introduced a bipartisan bill to regulate hemp-derived THC products, claiming White House support. However, sources indicate that the Trump administration has reservations about provisions related to inhalable products. The bill,
co-sponsored by Rep. Angie Craig (D-MN), aims to establish regulations for manufacturing, labeling, sales, and taxation of hemp products, with an age limit of 21. While the administration has called for a pause on the federal recriminalization of hemp THC products, it has not explicitly endorsed Barr's bill. The White House's concerns focus on the inclusion of inhalable forms of cannabis in the definition of legal hemp products.
Why It's Important?
The bill's introduction is a critical development in the ongoing debate over hemp regulation in the U.S. It seeks to provide a clear regulatory framework for hemp-derived products, which have been in a legal limbo since the 2018 Farm Bill. The administration's concerns highlight the complexities of balancing consumer safety with market access. The outcome of this legislative effort could significantly impact the hemp industry, influencing product availability and market dynamics. The bill's progress will be closely monitored by industry stakeholders and policymakers.
What's Next?
As the bill moves through Congress, it will likely undergo revisions to address the White House's concerns and gain broader support. Discussions may focus on the definition of legal hemp products and the inclusion of inhalable forms. A Senate companion bill is expected soon, which could introduce further changes. The administration's stance will play a crucial role in shaping the final legislation, with potential implications for the hemp industry's regulatory landscape.
